Navigation Links
Correction: Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System

MENLO PARK, Calif., March 25 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today CE Mark approval for its MitraClip(R) system. The MitraClip is the first commercially available device which enables a non-surgical option for patients suffering from the effects of mitral regurgitation (MR).

MR is the most common type of heart valve insufficiency in the United States and the second most common in Europe, affecting millions of people worldwide. Both in the United States and Europe, the vast majority of patients are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

CE Mark approval gives Evalve the ability to train and educate physicians in Europe on the use of the MitraClip device increasing the number of patients who will potentially benefit from this innovative treatment. Evalve will work with hospitals across Europe to establish training programs which will allow physicians to gain access to this new technology.
In addition to CE Mark approval, company highlights include:

-- High Risk Registry Study Arm Enrollment Completed: Evalve recently

completed enrollment in the high-risk registry arm of the Endovascular

Valve Edge-to-Edge REpair STudy (EVEREST) in North America. Patients

who are high risk surgical candidates may benefit from a less invasive

procedure. Investigators are collecting follow-up data to assess the

risk-benefit profile from the less invasive percutaneous intervention

with the MitraClip device.

-- Continued Progress with EVEREST Trial: The EVEREST investigators from

more than 40 sites across North America have reached additional

milestones in the ongoing FDA-approved Phase II clinical study. EVEREST

Investigators have treated more than 300 patients with close to 400

MitraClip devices implanted. Trial data continues to grow with a

significant amount of three-year follow up results available as well as

four-year data from some patients.

-- Presentation of MitraClip Procedure Results: Data regarding the results

in functional MR (ischemic and cardiomyopathy) patients will be

presented by James Hermiller, M.D., director of the interventional

fellowship program at St. Vincent Heart Center of Indiana in

Indianapolis, at the SCAI-ACCi2 annual meeting in Chicago as part of

the late-breaking clinical trial program on Tuesday, April 1. In

addition to the data presentation, Evalve is sponsoring a breakfast

symposium organized by SCAI on Monday, March 31 where MitraClip device

data will be reviewed. The "Understanding Mitral Regurgitation"

symposium is being chaired by Ted Feldman, M.D., national principal

interventional cardiology investigator for the EVEREST study.

"The progress we have made, notably the milestones achieved in the EVEREST trial and receiving CE Mark approval, are important as we move toward commercialization in Europe and the U.S.," said Ferolyn Powell, president and chief executive officer of Evalve. "We believe the MitraClip system has the potential to benefit patients who currently suffer from the serious effects of MR. Oftentimes patients in consultation with their doctors choose not to undergo surgical treatment because of the associated risks and trauma. However, until now surgery was the only available treatment option. The MitraClip offers the patients a new alternative."


EVEREST investigators are currently enrolling patients in the randomized arm of the study with the goal of completing enrollment by the end of 2008.
Enrollment in the study is open to several patient groups:

-- Patients with either degenerative or functional MR

-- Patients who are good surgical candidates and are open to the option of

a less invasive approach

-- Patients who are higher risk surgical candidates but are considered


More information about the EVEREST trial is available at

About the MitraClip Procedure

Percutaneous mitral repair with Evalve's MitraClip device is performed by interventional cardiologists in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Evalve, Inc. (Menlo Park, Calif.) was incorporated in 1999 to design, develop, manufacture, and market innovate devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair. For more information about Evalve, Inc., and for an animated explanation of the Percutaneous Mitral Repair procedure using the MitraClip device, visit Evalve is the first portfolio company from the medical device company incubator, The Foundry (

MitraClip and Evalve are registered trademarks of Evalve, Inc.

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Correction: Therapist to Young Hollywood Says Male Stars in Psychological Trouble Get a Media Pass as Compared to Female Stars
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Evalve Announces CE Mark Approval of the Worlds First Percutaneous Valve Repair System
4. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
5. UPDATED: Evalve(R) Completes $60 Million Series D Financing
6. Evalve(R) Completes $60 Million Series D Financing
7. North American Insurance Leaders, Inc. Announces Results of the Annual Meeting of Stockholders
8. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
9. International Eye Foundation Announces Partnership with Newport Creative Communications
10. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
11. Laerdal Medical Announces Strategic Relationship
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their ... surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for ... excited to rebuild lives and it’s an honor to have served all of these ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
Breaking Medicine Technology: